Research Nester released a report titled “Autoimmune Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global autoimmune disease drugs market in terms of market segmentation by drug, by disease, by distribution channel and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Autoimmune disease is a condition of the immune system in which it attacks the body’s own cells which might result in degradation as well as improper functioning of body organs. The market for autoimmune disease drugs is anticipated to record a CAGR of around 5% over the forecast period, i.e., 2020-2028. The market is segmented by drug, by disease, by distribution channel and by region. Based on disease, the market is segmented into rheumatoid arthritis, type 1 diabetes, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease and others. The segment for rheumatoid arthritis is predicted to hold the largest share and grow by the highest rate on account of high prevalence of rheumatoid arthritis globally over the forecast period.
Based on regional analysis, , the autoimmune disease drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market is anticipated to observe greater growth opportunities in North America on account of increasing research and development activities focused on finding a cure for autoimmune disease. On the other hand, the market in Asia Pacific is predicted to grow at the highest rate as a result of improving healthcare infrastructure and development of better treatment facilities.
Growing Awareness about Autoimmune Disorders to Expand the Market Size
According to Centers for Disease Prevention and Control, around 22.7% or 54.4 million adults in America had doctor-diagnosed arthritis as per the National Health Interview Survey 2013-3015, with a higher prevalence in women (23.5%) than in men (18.1%). The growing prevalence of various autoimmune diseases poses a high risk to individuals, especially the elderly population. Hence, there is a demand for reducing the effects of this disorder, which is anticipated to result in growth of the market. However, the high cost of treatment for autoimmune disease is estimated to hamper the market growth over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global autoimmune disease drugs market which includes company profiling of Abbott Laboratories, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, AstraZeneca plc, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Biogen and Amgen. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global autoimmune disease drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.